Q1 · CROSS-FIELD
ArticleOA
Author: Fischer, Marcus ; Wang, Xusheng ; Mullighan, Charles G ; Loughran, Allister J ; Mascibroda, Lauren G ; Hiltenbrand, Ryan ; Klco, Jeffery M ; Kalathur, Ravi ; Nishiguchi, Gisele ; Abdelhamed, Sherif ; Barajas, Juan M ; Shelat, Anang A ; High, Anthony A ; Zaman, Guido J R ; Thomas, Melvin ; Young, Sarah M ; Shi, Zhe ; Miller, Darcie J ; Caine, Elizabeth A ; Peng, Junmin ; Mayasundari, Anand ; Zhou, Suiping ; Rankovic, Zoran ; Daniels, Danette L ; Yu, Kaiwen ; Mishra, Vibhor ; Das, Sourav ; Pruett-Miller, Shondra M ; Urh, Marjeta ; Aggarwal, Anup ; Chang, Yunchao ; Riching, Kristin M ; Kooijman, Jeffrey J ; McGowan, Kevin ; Narina, Shilpa
Abstract:Molecular-glue degraders are small molecules that induce a specific interaction between an E3 ligase and a target protein, resulting in the target proteolysis. The discovery of molecular glue degraders currently relies mostly on screening approaches. Here, we describe screening of a library of cereblon (CRBN) ligands against a panel of patient-derived cancer cell lines, leading to the discovery of SJ7095, a potent degrader of CK1α, IKZF1 and IKZF3 proteins. Through a structure-informed exploration of structure activity relationship (SAR) around this small molecule we develop SJ3149, a selective and potent degrader of CK1α protein in vitro and in vivo. The structure of SJ3149 co-crystalized in complex with CK1α + CRBN + DDB1 provides a rationale for the improved degradation properties of this compound. In a panel of 115 cancer cell lines SJ3149 displays a broad antiproliferative activity profile, which shows statistically significant correlation with MDM2 inhibitor Nutlin-3a. These findings suggest potential utility of selective CK1α degraders for treatment of hematological cancers and solid tumors.